Portmanteau inhibitor

From Wikipedia, the free encyclopedia
Jump to: navigation, search

A portmanteau inhibitor is a drug that is a combination of two drug molecules, each of which is itself a type of inhibitor. The term was coined in 2007 by University of Minnesota researchers who designed and synthesized a combination HIV reverse transcriptase inhibitor and an integrase inhibitor,[1][2][3] and in 2011 by a team of researchers combining an integrase inhibitor with a CCR5 entry inhibitor.[4]

Footnotes[edit]

  1. ^ "U of M researchers announce advance in treatment of HIV". 25 July 2007. Retrieved 25 July 2007. 
  2. ^ "Researchers Discover New Method To Combat HIV". 25 July 2007. Retrieved 25 July 2007. 
  3. ^ Zhengqiang Wang, Eric M. Bennett, Daniel J. Wilson, Christine Salomon, and Robert Vince (2007). "Rationally Designed Dual Inhibitors of HIV Reverse Transcriptase and Integrase". Journal of Medicinal Chemistry 50 (15): 3416–3419. doi:10.1021/jm070512p. PMID 17608468. 
  4. ^ Bodiwala, H. S.; Sabde, S.; Gupta, P.; Mukherjee, R.; Kumar, R.; Garg, P.; Bhutani, K. K.; Mitra, D.; Singh, I. P. (2011). "Design and synthesis of caffeoyl-anilides as portmanteau inhibitors of HIV-1 integrase and CCR5". Bioorganic & Medicinal Chemistry 19 (3): 1256. doi:10.1016/j.bmc.2010.12.031.